🔹 Adjusted EPS: $2.22 (Est. $2.13) 🟢; UP +7% YoY
🔹 Revenue: $15.53B (Est. $15.33B) 🟢; DOWN -2% YoY, UP +1% ex-FX
🔹 Gross Margin: 78.0% (vs. 77.6% YoY) 🟢
FY 2025 Guidance:
🔹 Adjusted EPS: $8.82–$8.97 (Prev. $8.88–$9.03) 🔴
🔹 Gross Margin: ~82% (Prev. ~82.5%) 🔴
🔹 Total Sales: $64.1B–$65.6B
🔸 EPS outlook revised to reflect $0.06/share impact from Hengrui Pharma license charge
🔸 Guidance absorbs $200M in added costs from tariffs announced to date
Pharmaceutical Segment:
🔹 Total Pharmaceutical Revenue: $13.64B; DOWN -3% YoY, DOWN -1% ex-FX
🔹 Keytruda Revenue: $7.21B (Est. $7.45B) 🔴; UP +4% YoY, UP +6% ex-FX
🔹 Gardasil/Gardasil 9 Revenue: $1.33B (Est. $1.32B) 🟢; DOWN -41% YoY
🔹 Januvia/Janumet Revenue: $796M; UP +19% YoY
🔹 ProQuad, M-M-R II, VARIVAX: $539M; DOWN -5% YoY
🔹 Bridion: $441M; Flat YoY
🔹 Lynparza: $312M; UP +7% YoY
🔹 Winrevair: $280M; New product launch
🔹 Lenvima: $258M; UP +1% YoY
🔹 Vaxneuvance: $230M; UP +5% YoY
🔹 Prevymis: $208M; UP +19% YoY
🔹 Welireg: $137M; UP +62% YoY
🔹 Capvaxive: $107M; New product launch
🔹 Lagevrio: $102M; DOWN -71% YoY
🔹 Simponi: $0 (vs. $184M YoY); Rights reverted to J&J
Animal Health Segment:
🔹 Total Animal Health Revenue: $1.59B; UP +5% YoY, UP +10% ex-FX
🔹 Livestock Revenue: $924M; UP +9% YoY, UP +16% ex-FX
🔹 Companion Animal Revenue: $664M; Flat YoY, UP +3% ex-FX